Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hikaru Koga

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Antibodies (Basel, Switzerland)|January 22, 2024
Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig<sup>TM</sup> for Preclinical Screening of HER2/CD3 T-Cell EngagersHikaru Koga, Haruka Kuroi, Rena Hirano, et al.
Research and Practice in Thrombosis and Haemostasis|December 1, 2025
NXT007 enhances <i>in vitro</i> coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formationKazuki Yamaguchi, Kenta Haraya, Hikaru Koga, et al.
Gene|January 24, 2015
Sexually biased transcripts at early embryonic stages of the silkworm depend on the sex chromosome constitutionMunetaka Kawamoto, Hikaru Koga, Takashi Kiuchi, et al.
Mabs|August 22, 2023
Monte Carlo Thompson sampling-guided design for antibody engineeringTaro Kakuzaki, Hikaru Koga, Shuuki Takizawa, et al.
Nature|May 16, 2014
A single female-specific piRNA is the primary determiner of sex in the silkwormTakashi Kiuchi, Hikaru Koga, Munetaka Kawamoto, et al.
Mabs|June 20, 2023
Efficient production of bispecific antibody by FAST-Ig<sup>TM</sup> and its application to NXT007 for the treatment of hemophilia AHikaru Koga, Takashi Yamano, Juan Betancur, et al.
Ebiomedicine|November 8, 2025
Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement functionAdrian W S Ho, Taku Fukuzawa, Hikaru Koga, et al.
Journal of Thrombosis and Haemostasis : JTH|November 8, 2023
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic stateYuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Antibodies (Basel, Switzerland)|January 22, 2024
Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig<sup>TM</sup> for Preclinical Screening of HER2/CD3 T-Cell EngagersHikaru Koga, Haruka Kuroi, Rena Hirano, et al.
Research and Practice in Thrombosis and Haemostasis|December 1, 2025
NXT007 enhances <i>in vitro</i> coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formationKazuki Yamaguchi, Kenta Haraya, Hikaru Koga, et al.
Gene|January 24, 2015
Sexually biased transcripts at early embryonic stages of the silkworm depend on the sex chromosome constitutionMunetaka Kawamoto, Hikaru Koga, Takashi Kiuchi, et al.
Mabs|August 22, 2023
Monte Carlo Thompson sampling-guided design for antibody engineeringTaro Kakuzaki, Hikaru Koga, Shuuki Takizawa, et al.
Nature|May 16, 2014
A single female-specific piRNA is the primary determiner of sex in the silkwormTakashi Kiuchi, Hikaru Koga, Munetaka Kawamoto, et al.
Mabs|June 20, 2023
Efficient production of bispecific antibody by FAST-Ig<sup>TM</sup> and its application to NXT007 for the treatment of hemophilia AHikaru Koga, Takashi Yamano, Juan Betancur, et al.
Ebiomedicine|November 8, 2025
Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement functionAdrian W S Ho, Taku Fukuzawa, Hikaru Koga, et al.
Journal of Thrombosis and Haemostasis : JTH|November 8, 2023
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic stateYuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, et al.
Pageof 1